The ongoing clinical trial at the Abramson Cancer Center aims to establish the utility of frailty assessments in predicting treatment outcomes for older patients (60+) with hematologic malignancies, specifically acute leukemia and myelodysplastic syndromes (MDS). This research addresses a significant unmet need in oncology, as older patients often experience adverse outcomes from aggressive treatments. If successful, the findings could lead to improved patient stratification and personalized treatment approaches, enhancing market positioning for therapies targeting this demographic. The trial's outcomes may also influence clinical guidelines and reimbursement strategies, thereby impacting competitive dynamics in the hematologic oncology space.